The Impact of Stopping Zepbound: Weight Regain Study Reveals

A study published in the journal JAMA revealed that patients who discontinued treatment with Eli Lilly's weight-loss drug Zepbound experienced a 14% weight regain nearly a year later, while those who continued the treatment saw an additional 5.5% weight reduction. The drug, which targets the GLP-1 hormone to induce a feeling of fullness, is sold as Zepbound for weight loss and as Mounjaro for type 2 diabetes. The study highlights the need for longer-term therapy with GLP-1 drugs to maintain weight loss, as discontinuing such medications can lead to weight regain.